Regen BioPharma Valuation
| RGBPP Stock | USD 0.06 0 6.82% |
Regen BioPharma seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Regen BioPharma from analyzing the company fundamentals such as Current Valuation of 304.65 M, price to sales of 4.60 X, and Return On Asset of -0.76 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Regen BioPharma's price fluctuation is out of control at this time. Calculation of the real value of Regen BioPharma is based on 3 months time horizon. Increasing Regen BioPharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Regen BioPharma's intrinsic value may or may not be the same as its current market price of 0.06, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0601 | Real 0.0577 | Hype 0.06 | Naive 0.0659 |
The intrinsic value of Regen BioPharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Regen BioPharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Regen BioPharma helps investors to forecast how Regen pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Regen BioPharma more accurately as focusing exclusively on Regen BioPharma's fundamentals will not take into account other important factors: Regen BioPharma Total Value Analysis
Regen BioPharma is at this time projected to have takeover price of 304.65 M with market capitalization of 335.96 K, debt of 1.58 M, and cash on hands of 110.99 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Regen BioPharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
304.65 M | 335.96 K | 1.58 M | 110.99 K |
Regen BioPharma Investor Information
About 55.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.02. Regen BioPharma had not issued any dividends in recent years. Based on the key measurements obtained from Regen BioPharma's financial statements, Regen BioPharma is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Regen BioPharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Regen BioPharma has an asset utilization ratio of 42.13 percent. This connotes that the Company is making $0.42 for each dollar of assets. An increasing asset utilization means that Regen BioPharma is more efficient with each dollar of assets it utilizes for everyday operations.Regen BioPharma Ownership Allocation
Regen BioPharma owns a total of 158.73 Million outstanding shares. Regen BioPharma has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Regen BioPharma Profitability Analysis
The company reported the revenue of 235.52 K. Net Income was 2.44 M with profit before overhead, payroll, taxes, and interest of 235.52 K.About Regen BioPharma Valuation
The pink sheet valuation mechanism determines Regen BioPharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Regen BioPharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Regen BioPharma. We calculate exposure to Regen BioPharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Regen BioPharma's related companies.Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California. Regen Biopharma operates under Biotechnology classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Regen BioPharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Regen BioPharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Regen BioPharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Regen BioPharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Regen BioPharma's revenue streams: Identify Regen BioPharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Regen BioPharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Regen BioPharma's growth potential: Evaluate Regen BioPharma's management, business model, and growth potential.
- Determine Regen BioPharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Regen BioPharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Regen BioPharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Regen BioPharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 37.3 M | |
| Quarterly Earnings Growth Y O Y | -0.458 | |
| Retained Earnings | -20.9 M |
Additional Tools for Regen Pink Sheet Analysis
When running Regen BioPharma's price analysis, check to measure Regen BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regen BioPharma is operating at the current time. Most of Regen BioPharma's value examination focuses on studying past and present price action to predict the probability of Regen BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regen BioPharma's price. Additionally, you may evaluate how the addition of Regen BioPharma to your portfolios can decrease your overall portfolio volatility.